Dr. Pecora on the Pathway Inhibitor Cabozantinib

Andrew L. Pecora, MD, FACP, CPE
Published: Wednesday, May 18, 2011

Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center on the pathway inhibitor cabozantinib.

Dr. Pecora says cabozantinib is an agent that is capable of blocking multiple pathways at the same time. In phase I trials, it has been shown to have activity in a broad array of solid tumors. It will demonstrate that by targeting specific pathways within a cancer cell, you can actually block the growth and, in some cases, kill the cancer cell in diseases that had not been sensitive to other therapies.
Andrew L. Pecora, MD, FACP, CPE the Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center on the pathway inhibitor cabozantinib.

Dr. Pecora says cabozantinib is an agent that is capable of blocking multiple pathways at the same time. In phase I trials, it has been shown to have activity in a broad array of solid tumors. It will demonstrate that by targeting specific pathways within a cancer cell, you can actually block the growth and, in some cases, kill the cancer cell in diseases that had not been sensitive to other therapies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x